Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Durvalumab and Tremelimumab for Pediatric Malignancies

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03837899
Recruitment Status : Recruiting
First Posted : February 12, 2019
Last Update Posted : March 21, 2019
Sponsor:
Information provided by (Responsible Party):
AstraZeneca

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : October 18, 2021
  Estimated Study Completion Date : March 20, 2023